Loading
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Latest filing published 22 Jan 2025 for Coherus BioSciences, Inc., €6,570. Read the official filing
Insider track record
Disclosed buys
0
Disclosed sells
0
Signal history
Paul Reider: trading record in brief
All filings by Paul Reider on record concern Coherus Oncology, Inc. Over a trading history stretching from 1 April 2023 to 20 January 2025, the count stands at 7 filings.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
The newest entry dates from 22 January 2025: a share grant of €6,570, in Coherus Oncology, Inc. The median gap between a trade and its publication by SEC (Form 4) is 3 days. Section 16 rules allow two business days to file each Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Paul Reider
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations7 total
4,858 shares@ US$1.3913.1% of flowCommon StockSEC:0001610717-25-000014:0
2,277 shares@ US$1.667.3% of flowCommon StockSEC:0001610717-25-000007:0
2,073 shares@ US$1.616.3% of flowCommon StockSEC:0001610717-24-000542:0
4,854 shares@ US$2.4421.7% of flowCommon StockSEC:0001610717-24-000038:0
2,275 shares@ US$2.9212.1% of flowCommon StockSEC:0001610717-24-000018:0
2,049 shares@ US$2.378.9% of flowCommon StockSEC:0001610717-23-000401:0
2,451 shares@ US$6.8430.6% of flowCommon StockSEC:0001140361-23-016454:0
7 of 7 declarations
